Literature DB >> 11483723

Different levels of T-cell receptor triggering induce distinct functions in hepatitis B and hepatitis C virus-specific human CD4(+) T-cell clones.

H M Diepolder1, N H Gruener, J T Gerlach, M C Jung, E A Wierenga, G R Pape.   

Abstract

CD4(+) T cells play a major role in the host defense against viruses and intracellular microbes. During the natural course of such an infection, specific CD4(+) T cells are exposed to a wide range of antigen concentrations depending on the body compartment and the stage of disease. While epitope variants trigger only subsets of T-cell effector functions, the response of virus-specific CD4(+) T cells to various concentrations of the wild-type antigen has not been systematically studied. We stimulated hepatitis B virus core- and hepatitis C virus NS3-specific CD4(+) T-cell clones which had been isolated from patients with acute hepatitis during viral clearance with a wide range of specific antigen concentrations and determined the phenotypic changes and the induction of T-cell effector functions in relation to T-cell receptor internalization. A low antigen concentration induced the expression of T-cell activation markers and adhesion molecules in CD4(+) T-cell clones in the absence of cytokine secretion and proliferation. The expression of CD25, HLA-DR, CD69, and intercellular cell adhesion molecule 1 increased as soon as T-cell receptor internalization became detectable. A 30- to 100-fold-higher antigen concentration, corresponding to the internalization of 20 to 30% of T-cell receptor molecules, however, was required for the induction of proliferation as well as for gamma interferon and interleukin-4 secretion. These data indicate that virus-specific CD4(+) T cells can respond to specific antigen in a graded manner depending on the antigen concentration, which may have implications for a coordinate regulation of specific CD4(+) T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483723      PMCID: PMC115022          DOI: 10.1128/jvi.75.17.7803-7810.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation.

Authors:  D R DeSilva; K B Urdahl; M K Jenkins
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

3.  Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA.

Authors:  P H Van der Meide; M Dubbeld; H Schellekens
Journal:  J Immunol Methods       Date:  1985-05-23       Impact factor: 2.303

4.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Authors:  J T Gerlach; H M Diepolder; M C Jung; N H Gruener; W W Schraut; R Zachoval; R Hoffmann; C A Schirren; T Santantonio; G R Pape
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

6.  Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events.

Authors:  J Ruppert; J Alexander; K Snoke; M Coggeshall; E Herbert; D McKenzie; H M Grey; A Sette
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.

Authors:  B D Evavold; P M Allen
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

8.  Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation.

Authors:  E N Kersh; G J Kersh; P M Allen
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

9.  CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.

Authors:  K J Maloy; C Burkhart; T M Junt; B Odermatt; A Oxenius; L Piali; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  4 in total

1.  Schistosoma infection inhibits cellular immune responses to core HCV peptides.

Authors:  A Farid; M Al-Sherbiny; A Osman; N Mohamed; A Saad; M T Shata; D-H Lee; A M Prince; G T Strickland
Journal:  Parasite Immunol       Date:  2005-05       Impact factor: 2.280

Review 2.  The regulation and maturation of antiviral immune responses.

Authors:  J Lindsay Whitton; Mark K Slifka; Fei Liu; Alexander K Nussbaum; Jason K Whitmire
Journal:  Adv Virus Res       Date:  2004       Impact factor: 9.937

3.  Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection.

Authors:  Jane H Wang; Xin Zheng; Xiaogang Ke; M Tevfik Dorak; Jingjing Shen; Basmattee Boodram; Maurice O'Gorman; Kenneth Beaman; Scott J Cotler; Ronald Hershow; Lijun Rong
Journal:  Virol J       Date:  2009-05-01       Impact factor: 4.099

4.  Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Authors:  Anangi Balasiddaiah; Haleh Davanian; Soo Aleman; Anna Pasetto; Lars Frelin; Matti Sällberg; Volker Lohmann; Sarene Koh; Antonio Bertoletti; Margaret Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.